Societal preference values for advanced melanoma health states in the United Kingdom and Australia

Br J Cancer. 2009 Aug 4;101(3):387-9. doi: 10.1038/sj.bjc.6605187. Epub 2009 Jul 14.


Background: No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and unintended toxicities associated with treatment.

Methods: Using standard gamble, utilities were elicited from 140 respondents in the United Kingdom and Australia for 13 health states.

Results: Preferences decreased with reduced treatment responsiveness and with increasing toxicity.

Conclusions: These general population utilities can be incorporated into treatment-specific cost-effectiveness evaluations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Australia
  • Cross-Sectional Studies
  • Female
  • Health Status*
  • Humans
  • Male
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Middle Aged
  • United Kingdom


  • Antineoplastic Agents